Alza Brings Ditropan XL To Abbott As Near-Term Project In $7.3 Bil. Merger
Executive Summary
Abbott would expand its urologic products franchise with the urinary incontinence treatment Ditropan XL as one of the immediate effects of its proposed acquisition of Alza.